PSTV - Earnings call transcript Q4 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen, and welcome to the Plus Therapeutics Fourth Quarter and Full Year 2021 Results Call. At this time, all participants have been placed in a listen-only mode, and the floor will be open for your questions following the presentation. [Operator Instructions].

Before we begin, we want to advice you that over the course of the call and question-and-answer session, forward-looking statements will be made regarding events, trends, business prospects and financial performance, which may affect Plus Therapeutics' future operating results and financial position. All such statements are subject to risks and uncertainties and including the risks and uncertainties described under the Risk Factors section included in Plus Therapeutics' annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission from time to time. to risk you such in advises statements. Therapeutics review factors these considering Plus no or the to statements Therapeutics responsibility Plus assumes update made. events, or are to trends revise circumstances they after date reflect forward-looking any It is the to Dr. to floor over my now pleasure turn Plus Hedrick, and Therapeutics' Executive President Officer. Marc Chief Sir, you begin. may

Marc Hedrick

fourth overview afternoon discuss Thank to as today join Good you and of business again and everyone. quarter an highlights recent very XXXX financial you David. for year once our us we Thank much, results. taking time full provide the

Joining our me Andrew on the call today Chief is Sims, Financial Officer.

Andrew on plus time joined new In and addition, the LaFrance, Medical for Chief call at first the Joining Dr. our Norman I the end who today of Officer is XXXX.

LaFranceon of reviewing in to the aboard many will for and call We Welcome as the board to clinical are in very highly of our team. by clinical Norman. expertise commercial he the clinical Plus years begin excited turning radio and expectations therapeutics the regulatory oncology remainder Dr. our XXXX. I'll have Norman management relevant commentary recent on brings before corporate Therapeutics call provide who to progress

XXXX, rhenium significant radiotherapeutic and continue toward global targeted our U.S. Following review will or our marked financials. we trial. to developing precision we investigational our in leader ReSPECT-GBM advance NanoLiposome lead drug for as XXXX Norman, In has therapeutics RNL been XXXX by cancer. mission to Andrew a our progress work early Rhenium become in radio targeted

a dose is Institute. multicenter volume dual or the is the cohort, sequential open currently significant escalation trial U.S. of The and Cancer reminder, NCI study. a X/X degree National trial a funded to As label Phase

escalation. X/X November. be patients Neuro-oncology at the data And New recently the this to at in the Education Phase ReSPECT-GBM most trial with presented XXXX on Day, and can those of found Both month. for Meeting presentations conference the clinical updated website. last now data York set we GBM the the BIO our CEO XXX grade then the to the tumor tumors recurrent interim in up Annual milliliters of Society radiation was According RNL, with XXX to the XX.X failures An delivered of is correlated delivery XX.X trial least enhanced course dose radiation No millicuries is unmet number locally absorbed patients and saving of were three treatment is via Average average RNL absorbed and the patients observed. delivery to and that emitter, the via beta are also which with significant is form of provided challenge. rhenium-XXX lethal common brain electrons, is remains RNL interim We enhanced which about initial both annually that is convection are energy in brain dual same It cancer encapsulated, the recurrent localization delivery. bypassing disease XX,XXX the proprietary of cancer. activation glioblastoma Our the positive this dosimetry. It's We imaging, Europe. barrier. tumor, the data killing as most U.S. administered The as call delivered directly regionally liposomal indication particles, the a and blood releasing targeted isotope, high in to feasible, of of thus over increased gamma a set from at far. to useful volume. approximately radionuclide dimensional convection defects is for well energy for and which the dose And delivered particles,

external to can in deliver setting. beam the shown with up we've fact, times traditional recurrent dose radiation that or deliver XXX successfully one In radiation XX of we amount can gray,

of There's multimodal for works no therapy better overall trial. survival. the day drug in without And about glioblastoma, safety ReSPECT increase et the as were remains and a cetera, therapies well also survival. in in improved As best this catheter, with five those been There toxicities, catheters outcomes were discontinuation Furthermore, trial, rate, correlated therapy adverse to improve other has And safe. that studies outcome delivery currently that key GBM. with about far the during indicate published in XXX radiation far events, is thus limiting improvement all it survival component of profile. available an such EBRT which an far increased aside months no death, delivery thus cancers. radiation acceptable beam question drug flow provides course external of a up and tolerated trial GBM and adverse parameters in radiation patient or of four of events, to many the central placement thus the due to for in have and RNL incremental

and That received it's take the the take thus and remaining the in we academics Therefore, and assess this interesting at GBM, least current XXX have step survival was do trial, our is mean a -- the of trial XXXX, back continues As and of trial physicians parameters. with respect very XXX treated med cohort specifically date Bevacizumab is from five effect overall and dose in which And survival radiation neither recent dose far, In eight, in greater were in to on initiated a entire excuse far longer with that's the long-term They to promising therapeutic advantage results XX% our in XX done data excellent alive. observing respectively, better patients treated greater absorb And bone median which progress our in frankly increased delivery or weeks to of and of Well, GBM as XXX And of published greater scale up by presentations. XX me, with and and our five similar, at the the and we to mean biological to radiation. gray radiation note academic survival. patients the recurrent XX interestingly team possible in volumes it's is radiation. currently alive. or survival increased cohorts, X optimized efficacy, a overall the I are overall found mentioned, It's and better. weeks trial. in subset the can very the by XXX drug this results which treated favorably received such every seven initial we nearly more it's or of the thus weeks gray patients in the This who which to believe Total greater with March XXXX in group efficacy median respectively, stands for logical survival. XX XX we of weeks be through of recurrent in what's the of those patients the minimum corporate that in for survival range of coverage of with setting. than Phase trial monotherapy recurrent been the overall with patients XX therapeutic signals XX% start analysis, entirely unusual efficacy, than the powered XXXX, overall started still data survival trial preclinical immediate to that drug two receiving patients who gray are XXX we of compares subjects five Furthermore, doses, a in Nine overall cohorts patients at make both XX in latter gray cohorts are and reference designed have July it's manufacturing through forward. a achieve eight, dose website activities. far

as collaboration remains into by in pretty with mid-XXXX. practices the funny during analytical to multiple stage XXX GMP strengthen in to chain process development GMP entered company as supply one late XXXX, deliver track agreements well in this for activities, RNL planned on The in company trials. our support its Specifically to clinical compliance chemistry

Before to for the the you Norman, policy announced call December. will expands he the highlight I'd consummated This of portfolio. we end that I over turn right January, XXX at agreement beginning our forward update like substantially of RNL. on the the path to

compounds supplied organ breadth blood using leverage very resorbable BAM of blood extended an we tumors a is the all to deliver target microspheres, BAM Therapeutic cancer, licensed are later, alginate precisely this interventional generation before, most the days to patents initially for into for composition methods can isotope. of technology, with the develop biodegradable the loaded vascular radiologic technology focus simultaneously therapeutics also which and delivered while BAM, which killing end, blocks body include be in BAM liver radio any believe with and malignant the therapeutics feeding and as directly while precise to system following metabolized therapeutics. stated worldwide high standard of the to call the interventional in BAM system flow potent blood blocks and into developing placed containing tumor injected, next may we physiologically that fundamentally cytotoxic cancer future thermal BAM vascular resorbs the coupled Texas the XXX the or both and embolic license company a artery for payloads to the a then with therapy tumors patents decay, vascular irradiating full vessels potent cancer University an payloads. for RNL a The the Once segments delivers nanoliposomes providing minimizing we agreement radio exclusive RNL biomaterial radiation therapeutic chemotherapeutics, are in targeting commercialize tumor. from for matter excreted to of body. technology doses highly and that we the standard To on tissues. radiotherapy technology the With The our in tumors. time. via the include period Many will is to we of is hepatic novel As the of normal human going almost solid damage tumor, cancer. radioembolization of agents entered with The XXX in interventional imaging

enabling program to steps transfer from TID with this Next academia over are technology call the and CMC that, completing preclinical and work. turn Norman. And I'll in

Norman LaFrance

have today to is is I'm to the radio therapeutics focused joined Plus Marc. lead expansion positions Therapeutics joining to on call. here this I'm delighted pipeline. for Therapeutics you, excited and long-term firmly Plus its be Thank growth. promising to of you development

indications. drug the In to recurrent glioblastoma. GBM and on we patients materially in Following other with trial recurrent Marc’s ReSPECT-GBM investigational RNL XXXX, comments advanced the XXX expect

our with First midyear taking appropriate dose. meet based this of on we patients proposed is We XX.X Phase morphology. recommended to as with millicurie size XX% XX% milliliter and and for glioblastoma our to dose plan recurrent X believe X.X FDA tumor

As currently to trial improve Phase we costs also exploring X incorporate earlier trial designs known world week, the control facilitate real that to use are potential arm may data, publicly of this synthetic announced pivotal as enrollment.

anticipate and benefit improve the and we treat to administrations review trial of RNL. larger disease potentially new two to may reach a in GBM we is GBM our on benefit able to allow We RNL cohorts. addition, other to potential with use the terms previously report efficacy XXX consider clinical data parameters. more In filed subtypes dosing escalation and expand in the they open to recurrent the to with patients XXX of respect drug Recently, additional treated safety for to both from to XXXX, Phase Furthermore, us patients And those the GBM treat dose. or a be and a we on XXX is a RNL, dose greater have goal FDA subset eradicate keep as will notoriously we following of with an previously RNL. company believe patients as toxicity, of XXX have difficult glioblastoma brain. yet treated the protocol limiting X also future trial, exploring the tumors RNL

U.S., acts. can XXX indications, patients involvement to secondary is range increasingly leptomeningeal in and additional present a and simultaneous the metastases multiple areas is spinal year pediatric cancer. brain affecting patients developed RNL per over broad with Regarding cranial also an in of metastases signs cancer, the Leptomeningeal due for common symptoms XXX,XXX and of

dose, tolerated safety open trial XXX the the limiting single and for of label or if surgical metastases treatment one multicenter single the RNL intraventricular escalation radiation feasible serious and administration Leptomeningeal dose cohort, is LM severity of and expect adverse dose will standard phase is of evaluate these events and the sequential chemotherapy study incidence and treatment, maximum dose, the maximum dose, primary catheter adverse of efficacy endpoint metastasis any. patients. study We via a events following The

response overall survival, progression include endpoints survival. free Secondary of response rate, overall duration and

have we received treatment for addition, for of track FDA XXX fast In metastases. leptomeningeal the designation RNL

and the with in Following clearance on leptomeningeal respect screening and the last FDA company began quarter the consenting year, of last in patients patients IND Phase from metastases. year, trial fourth X

pre-IND expects brain use XXXX. feedback X Phase received cancer, submit of the results. in our and with for Company this and trial Andrew. the IND brain RNL I'll turn with meeting the At point, for the to Andrew cancer year to for XXX stop brain investigate to kids an brief treatment review pediatric over pediatric of call RNL Regarding on cancer. full of based on year financial a this

Andrew Sims

Please Thank you, for XX Norman. afternoon, to December today for our a press full good issued our refer ended summary the everyone. results And of XX, year release financial XX. earlier

XX, the and and cash follows. compared raising its XXXX, for XXXX. company XXXX were million, $XX.X approximately $XX.X compared $X.X to of used in XXXX as by was capital. sheet equivalents million early As The ended million to Cash XX million, strengthened of XXXX December of XXXX. operations changes XXXX balance between to $X.X In XX, December $XX.X XXXX, cash as in main months the December million XX,

to company's As professional $XX XX, over full was to expenses XXXX off CMC recruiting $X.X $XXX,XXX G&A development to NCI $XXX,XXX expense from the BAM approximately $XXX,XXX the to in primarily by $X.X XXXX. years XXXX XXXX These XXXX This for XXXX, in due Net XX, together related principle year on approximately increase XXXX. paid XXXX. is net completed a decrease this by Please principles filings, million the and primarily year compared be note $XX.X cost in for XXXX, was in to XXXX, the of of as Research million XXXX. of were to further million of This This payments Interesting $X fees with million in $X a as million employee increase continue fees. and standard. due is to XXXX and balance remaining year below January leverage activities. due December The run-rate Oxford company million in reduce for loss the expenses in awarded loss development for million pre-clinical XXXX. two XXXX. RNL transaction, compared GMP other to development $X.X to to as legal million patent remains five $X.X that grant cash. continues with new $X.X summer to the in XXXX. in decreased million minute our the expense also to cash $X.X million operating represents track is XXXX compared in expenses reflects at

the on back change gains in $X.X we’re quarter of warranty incremental the as Excluding And the loss the Marc. million and now that turn and to earlier G&A net mentioned XXXX, reported the I'll it R&D in of first reflects you,

Marc Hedrick

Thanks, gentlemen.

XXXX. to let on key Q&A, move anticipated me we summarize for just Before some milestones

these think already. I touched most we've of on

mid-XXXX. we First recurrent planned. the of And drug the all, in as on GMP to have the track with availability, ReSPECT to clinical XXX RNL Phase XXXX respect clarify XXX, CMC for trial second that as a RNL remain GBM, resolve activities plan FDA complete regarding issues any to CMC-focused the X quarter exist drug open that time. currently We CMC of supply meeting available in of and may by

LaFrance also meeting recommended clinical We Dr. and using a dose clinically to Phase plan Phase midyear a and trial plan X.X focused millicurie as propose X ml noted. XX.X FDA X design

enrollment in ongoing Phase regulatory potentially the use we and provide an XXXX, the to also costs. to X Phase in data which Phase of ongoing power continue plan in manner X accelerate enrollment data, X plan clinical We world the updates is current to report to explore In real plan trial. and and reduced

LM RNL trial. ReSPECT-XXX the Regarding

this to cohort of at year. initial enrollment is least the complete in Our patients the three goal

brain in pediatric an soon trial, IND to XXXX, initiate Regarding we thereafter. the and plan trial submit this cancer

the we in Regarding recently technology XX. XXX transfer asset to put acquired our in FDA complete BAM rights for and CMC, enabling IND to key RNL radioembolization in studies technology therapy this other the

you. turn over So it at David, I'll And to this point, to Q&A. move

Operator

The questions. saying. by Andrew While by B. email Walsh you. queue have we previously received be questions Thank a asked [Operator is open floor will for This Instructions] Riley. question from Justin live now with

Andrew Sims

Thanks, David.

from to you be? potential you us training is question barrier expect physician And of surgeons can well First use of make to how a to would equipped asset? the adoption, much Justin, are reminds

Marc Hedrick

is there soluble. years a a XXX% think it's our got barrier, ways. working under of but belt so with technology. two in this Yeah, And we We've it experience couple of novel about

First of all, there's aspect. the neurosurgical

really getting tumor. the second about The the part is which planning on case aspect, is radiation

very have in technology aspect, place brain true It's neurosurgical terms getting essentially there The existing, tumor catheters -- and technology. tried of surgically allows in the that hospitals common the biopsy So neurosurgical getting so leverages the itself many in services. used. we'd sort allow -- technology, or millimeter prefer so. navigation a the that brain that's the that be place geospatial systems of delivery one about are within there to precise And delivery labs actually, we've technology that

the gone I've doing feel trading after XXX% difficulty] [technical a my of of through I I’m that. neurosurgeon fact, capable training In and day full on

do difficulty] was [technical we it barrier. years think of with that reliably asset in think initially when how about is the adequately we the of told ago ensure the we ReSPECT amount don’t data. clinical acquired that I planning? of the tumor story radiation? is about cover trial case two part What I So And How is kind the can maybe worried appropriate

adequate et time. look If you the look I radiation doses, where cohorts than gray comfortable, cohorts. referred in therapeutic wider But flow And radiation, that plus seven, XX% to radiation in more greater We're like higher five gotten radiation think script, XX% were able rate, cover XX% I cover the increasingly achieved. this I'm think to catheters, about the get the to we're we've about with at that's the at only those adequate going able to four, got cohorts, we of if you able to where greater one tumor time more with of through or to just volume. cohorts, back the Justin, XXX cetera. to tumors We've higher

case neurosurgeon. we'll control we that in in now do currently be implementation really centrally. be of know, And through consultation just confident trials, the and way very we of that been well do going corporately that. think planning, the barriers may So have model quality the treating clinical do solved. commercially. perspective, to terms We the it's don't with important, We And but on we're basically, those forward or that the are that

Andrew Sims

question second provide some regulatory a you are of potential advantages design color synthetic can disadvantage that Justin’s for trial using some is, additional What of a on approach? control precedent the arm? and

Marc Hedrick

Normally, would you mind answering that?

Norman LaFrance

to. real be in by great precedent X and already has world established data to ovarian with for the X OVATION control this the Justin. bottom Thanks. of successfully synthetic happy with question It's line I'll the Yes, and credit arm be that FDA. in glioblastoma. Athena jump their right cancer, a interaction aware I'll may the also study, on Folks call Celsion's Gen asset, data

used with has with review this and FDA. been approach groups within glioblastoma So drug [Indiscernible] successfully seizure recurrent

you spend our allow and to if on be particularly an valuable, Now me will world second general, SCA application. one go approach real over in why focusing

have data this that the that an mentioned phase had is the single that control are as world our early be a enrollment respecting data Marc their Marc existing in able not dealing who thing of designed So understanding synthetic of criteria efficacy Phase will Phase have arm, arm, the group data And to advantage with that we X. mentioned. arm the rectify we'll trial to we are significant with first with this that doesn't control X, group, take do expert with for this the and

with to we'll the generating that's X the justify very have control analyze a this phase with with and arm be Annual one we beyond data to strong SNO to benefit Phase FDA. demonstrating survival year -- believe additional impressive overall the at capability been reported to advancements last This validation. will data overall begin all the So leads Meeting survival synthetic

arm X would As be encourage one-to-one. advancement. for of and enroll you control active pivotal we treatment. That not on and that this the development save decision. their This It's availability like turn Phase from market and will for understandably by heard faster means in to plan The will a midyear active I, personal randomization treatment costs. unfortunate patients both commercialization accelerates these development FDA Marc control a to Patients studies. always approaching

approach, don't even know the helping it, I I have have on valuable. is anticipated. I development for we great expectations move but you faster reasons of if Marc, that's think else this lot than So a that anything And think, why

Andrew Sims

follow it's That's question. up Thank a Maybe great. you.

So it questions. to the David, for turn back you

Operator

Of ahead. course, from question take Group. we'll our Maxim with live go Please Li first phone Jianing

line open. Your is

Jianing Li

question Hi, data quarter, the this especially presented taking Jianing, thanks progress at the on for the is and positive the SNL. congratulations on this

repeat And rate gray Given be on the dose on survival XXX strategy moving? for you recurrent that particularly briefly could but goalposts Will greater color cohorts, and at survival overall as I dosing trial? keep the GBM or of -- you this, if what survival know at touched the will shed you you setting, in the be overall in next what higher it meaningful could above extension volume? considered could some the

Norman LaFrance

Thank Yeah, Jianing. I'll take that. you,

trials is radiation. the moving of millicuries. eight think at X half plan the now, in I right and scheme. sufficient is up millicuries take we're of the CC's. through other walk interested continue move so which dose, think the trial, the we about designed degree prior CC's dose that's that dosing XX so what you're right six is. at X, that now, Phase the into back I cohort of recommended X And Phase a is So we the XX part which what XX volume, you And plan, we bifurcated the to to have it's to patients, first the the dose can Phase the about And I the of escalation continue dosing But which question, -- current X.X bifurcation, into

need shows of a but microscopic dosimetry treat also got appears The clinical DLTs, but by likely accessible is the survival only and disease, brain cover can that tissue very the trial imaging, very we to tumor, well long-term we've data the we that as know to we a get normal from safety that got not rim to harbor the we've profile. benefit. So

we perhaps XX think XX% sized will about up dose of medium a is we treat we'll dose small think millicurie difficult based So to have Phase the to tumors, the its that for current to have on recurrent with [ph] XX and X appropriate continue as XX, GBM, typical far. take we tumors data totally effort get more And complex to into the to are treat dose X.X morphologies escalate larger in are dosage. or potentially to the volume that that that's

So as terms in of target of radiation. the amount to the

interesting mentioned or seeing significant seems that So XX delivering showed a that escalated good start exactly to I over the patients to on the we interesting, preclinical grays tumor. that there's is, therapeutic. a at to with directly deliver we've thing And same in pretty we're gray the that seemingly the safety a survival, And XXX do we're And this as XXX you improvement grades. statistically now XXX profile. the data dose the pretty greater thing It's been able script, derived you biologic point. when But fact in. signal be only clear as

the that's going plan forward. So

any If to questions, up to happy follow you further address have try those.

Jianing Li

next GBM. approval? a an And give approach open indications some as need drug follow patients as arm the data seen a a setting unmet severe get recent you the and registration mentioned control for the in current study the you just through that years, pathway. And details you particularly around a more in Great, observed. we've Because, be we've da do approvals and recent could the XXX of up, trial screening regarding and us Can size GBM? in in that use with other trial, and Ahat decision? single the just to

Marc Hedrick

said forth. I believe is early patients, to no have budget size we of about Yeah, this from we've differently But approximately little looks reason trial. think so previously, XXX the a still the tell that too we believe to like, that trial size it's this, what

fast what have that know a the And data previously, about here status we've the believe, be have for FDA. with we We mentioned As that we an on breakeven may we as track that indication. the based and well. for program designation designation alternative pathway,

and world synthetic to the that the group. using to randomize. have control inclusion we're design real arm, might of with that approval synthetic question Phase the world able control go is enrollment the the patients criteria X a that the we arm real control be total to that offset to to identically criteria, as as from an on So supplement mentioned, control But been into And Norman have that's The synthetic Norman trial. to the of what patients a FDA this of exclusion amalgam that kind your group data now. randomized received thinking number Medicina to arm, up control right are follow alluded matched a to

where be in more here worn confident particularly we're the there's well we that's path So that FDA increase -- GBM. increasingly I think going useful well. to in like diseases they've we an accepted the think it, And that as of

Jianing Li

Great.

again. helpful. very Sounds Thanks

Marc Hedrick

you. Thank

Operator

our question Lee ahead, next We'll from go Please take H.C. is Sean with your Wainwright. open. line

Sean Lee

my Good afternoon, guys. taking And thanks questions. for

So plans. couple I a your of clinical just have development

try your first you question reducing wanted the mentioned is, patients. guys So to you

Now, Phase that within that? do study, in expect X we sometimes means that the cohort for same

Marc Hedrick

in sense that be Sean, the it Phase it’s It protocols, covers forth. design to the separate outside the X so a and would be be Marc, would it Hey,

framework. And so I end don't we the -- don't that NCI up back into

about back the And with separate heard but we move forward a protocol, been So from just -- under we submitted. IND. that's ability would it our be to the that. And FDA

Sean Lee

see. I

on? doses In kind of And what them studying of to of you terms what you looking of redose? particularly what sort will kind are patients -- that, be

Marc Hedrick

It's great a question. So, yeah.

that survivor, we So kind had it's survivors, a escalation though XXX GBM. still almost long-term of weeks that's even eradicate can't one to out we've that it. dose of seen And almost years that's impossible number trial we've eradicate three why in a

they're tumor, there so challenging, kind the those of morphology is where right And the we the the know so back might is and ideal. for [Indiscernible] we to cover right dosimetry patients, we tumors that's bit And location Difficult hyper be a maybe little off want patients the two on to not type anatomic forth. to of that risk there we patients. of be that bat data sets a could may where be may so be the going off based that vigilant retreat be area know recurrence recurrence -- on the patient problem, there at

where type The ready signal the in does if to them. be potentially we safety got as retreat it want of a seeing patient. But efficacy we’re does, patient back, we've to that comes particular and other Patient coverage. is disease typically well, good

is take the retreatment be planned six have down the cohort where into the the the we're patients take requesting But So taking recurrent dose. the going maximum Phase would plan -- we based the go does, be here that that treated, could that's to the that six would one to on protocol. the potentially tumor. dose We size maximum of recommended image X

Sean Lee

Thanks see. for that. I

in these also Phase the testing retreatments study. X of terms doses higher In testing and

I these treatments, X guys some with, see are do improved so mil or are off? you you your Phase delay from happy X.X you incorporate would to If outcomes set these you think that

Marc Hedrick

happy that. with we're Yeah,

of the think primary about the concept appears again, what I've a this rim it's around have centimeter in is you think normal mentioned and But the XX% that -- XX% that occur tumor we've tumor want this. mean, I of cover recurrences because size the tumor. be brain to and patients will to before, dependent. X I talked I

size much want cover tumor very a that issue. to that's we So

at So tumors. doses, and volumes, can we bigger higher treat higher

So able be is and But escalation and arm to treat get so XX those higher in escalate imaged that's tumors. continued retreatment rationale the the to these days. those context, patients every

first that we So knock requirement we would be would we jumping perhaps be requirement recurrence. and dose vigilant can that -- recurrent be that might to volume treat the bit be anything disease a and able than the and down think be would we dose and less radiation what a aggressive think the in on

Sean Lee

last product. see. clarification. Thanks the on for I question is the My BAM

issues they it, may while in rare from be and move first one U.S., the it's cancer And very of here guys Japan, will with after Asia, especially quickly. So go of very a sounds you out in product. the one this China cancer that it's common the liver

So test guys it something international collaboration something consider? be like those would countries in to that you

Marc Hedrick

I completely agree. as thinking consistent That's with our well.

partnering think transfer, that IND-enabling then early fact, on we're even is that interest But note other we've tech had as early still the in and already it In studies. I cautionary the is. the as

a year have include kind ready I don't we clinical But wouldn't work before So plan. in not a where Asia-Pacific of discuss would publicly include that of I still we're a trial the sites region. plan to trial we think scenario see

Sean Lee

I see. have. Thanks. That’s all I

Marc Hedrick

Sean. Thanks,

Operator

go Woo from Ascendiant next take [Operator with our Instructions] We'll ahead. Ed Capital. question Please

Your line is open.

Ed Woo

Yeah. Congratulations so on progress far. back Also the touching the on product. BAM

guess, of does in balanced terms how the was liked for your this of it really with priorities terms we out in in I terms And XXX what rationale you guys what company? So of see RNL should this? about

Norman LaFrance

for used BAM is mature, question. The excited Yeah, opportunity. the delivery very individual technologies all the radiographic about Thanks we're time. technology the very

The As although confident organ opposed very to It the technology. new XXX, which novel work. very solid of going we're for it’s very technology, effective mature, targeting. is sort to angiographic RNL individual is

It's I or about noting that XXX current thing other So this really excited us this. the a much this extension is, our technology is very technology. that of aligned I on. -- the that's thing is very guess sort is with an think RNL bolt worth key

have does technology. development And from clinical already our alley our on expertise as perspective, up a the So we portfolio. an this add up drug perspective, so CMC it is internally, right from really beef IP

that the area, cancer It's a issue, to but are right. disease. shortcomings. There have some products rare approximately been liver years absolutely significant for commercially, liver cancer have pretty broadly in As used they XX

right so differentiation over for the number second improvement market a that potential technology like And those. generation, of a a carries is points really of

does gives scale transfer with a before for steps but XXX. a isotopic we different next road make previously, the So concept early this nanoscale, XXX proof to in the target completely easier us have is provide then think experience generator before too work year, micro mechanism and year, properties XXX a for actually made late, than the far features the than I as us clinic, for the I consistency couple opposed a get technology. things think do a related of gain the scheduled we allows technology. nuclear and we reactor, isotope it though, us. is we which It of benefits the some on balancing It as hopefully, which drug and CMC targeting that at of is get of late XXX complete not that the to the physical next different scalability terms down to us much I the has different XXX product tech in different ex-vivo In into drug of and XXX and think mentioned is

current it's So XXX very technology. expansion logical a our of

Ed Woo

you. for Great, explanation. you wish guys the thank I Thank And good you luck.

Norman LaFrance

Thanks, Ed.

Operator

Hedrick no turn Instructions] back further [Operator floor Dr. time. questions there additional this are And or on to remarks. at line I'll for closing any the the

Marc Hedrick

David. you, Thank

Let members, team we're LaFrance, employees our patients enter and thank grateful work trial. with we by today. for version. welcome thanking our And us call board the just on Dr. like recorded the behalf is joining physicians you us course, to trust the always the And me that I of that clinical the of our for and on everybody listening that to into thank close specifically

thanks So your evening. and have participation again Bye good bye. a for

Operator

you today's may And conclude for program. This disconnect. Thank now you does participation. your

Plus Therapeutics (PSTV) 25 Feb 222021 Q4 Earnings call transcript